CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
OC-CTLsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03362606
NCT03362606Phase 1RecruitingMonitor
Slow Enrollment
CompareCT.gov

Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)

Shenzhen Geno-Immune Medical Institute·interventional·Posted Dec 5, 2017·Updated Jun 23, 2026

In Brief

A Phase 1 clinical trial evaluating OC-CTLs for Ovarian Cancer. Currently recruiting, targeting 20 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer specific cytotoxic lymphocytes (OC-CTLs) in women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--

Timeline

Phase 1Recruiting
20182019202020212022202320242025202620272028202920302031
First PostedDec 5, 2017
Enrollment StartJun 1, 2026
Primary CompletionDec 31, 2029
Study CompletionDec 31, 2030
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 8.6 years agoPrimary completion in 3.5 years

Arms & Interventions

OC-CTLsexperimental

Autologous ovarian cancer specific cytotoxic lymphocytes

Biological: OC-CTLs

Interventions

OC-CTLsbiological

2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, abdominal cavity or tumor injection each time